Forest Laboratories acquired by Actavis for $25B

02/19/2014 | Reuters · Genetic Engineering & Biotechnology News · Bloomberg

Generic-drug manufacturer Actavis agreed to pay approximately $25 billion, or $89.48 per share, to purchase Forest Laboratories in a cash-and-stock deal expected to be finalized by the middle of this year. The acquisition will combine the firms' growing specialty pharmaceutical portfolios and will give Actavis a major focus on higher-margin, brand-name drugs for Alzheimer's disease, high blood pressure and more. "With this strategic combination, we create an innovative new model in specialty pharmaceuticals leadership, with size and scale, a balanced offering of strong brands and generics," Actavis Chairman and CEO Paul Bisaro said.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News · Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA